Bolt Biotherapeutics is a clinical-stage biotech company developing immuno-oncology agents to target tumor cells for elimination by the immune system. Its pipeline includes BDC-1001 for HER2-expressing solid tumors, BDC-2034 for colorectal, non-small cell lung, pancreatic, and breast cancers, and BDC-3042 for repolarizing critical cells in the tumor microenvironment. The company is also developing a programmed cell death-ligand 1 program for nonresponsive tumors. Bolt Biotherapeutics was founded in 2015 and is headquartered in Redwood City, California.